133 related articles for article (PubMed ID: 34911829)
1. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
Reitz S; Schwantes A
PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
[TBL] [Abstract][Full Text] [Related]
2. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
Roush D; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the 2019 Viral Clearance Symposium, Session 2: New Modalities in Chromatography and Adsorptive Filters.
Specht R; Schwantes A
PDA J Pharm Sci Technol; 2022; 76(4):306-314. PubMed ID: 34911828
[TBL] [Abstract][Full Text] [Related]
4. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
[TBL] [Abstract][Full Text] [Related]
6. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
7. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the 2009 Viral Clearance Symposium.
Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
[TBL] [Abstract][Full Text] [Related]
10. Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding.
Roush D; Blümel J
PDA J Pharm Sci Technol; 2022; 76(4):323-338. PubMed ID: 34911824
[TBL] [Abstract][Full Text] [Related]
11. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
12. Proceedings of the 2019 Viral Clearance Symposium, Session 3: Continuous Processing.
Lute S; Specht R
PDA J Pharm Sci Technol; 2022; 76(4):315-322. PubMed ID: 34911830
[TBL] [Abstract][Full Text] [Related]
13. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
Schwantes A; Specht R; Chen Q
PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
[TBL] [Abstract][Full Text] [Related]
14. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
O'Donnell S; Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
[TBL] [Abstract][Full Text] [Related]
15. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
16. Viral clearance capability of monoclonal antibody purification.
Cai K; Anderson J; Utiger E; Ferreira G
Biologicals; 2024 Feb; 85():101751. PubMed ID: 38387156
[TBL] [Abstract][Full Text] [Related]
17. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
O'Donnell S
PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
[TBL] [Abstract][Full Text] [Related]
18. Integrated viral clearance strategies-reflecting on the present, projecting to the future.
Roush DJ
Curr Opin Biotechnol; 2018 Oct; 53():137-143. PubMed ID: 29367164
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
